
    
      The investigators new therapy regimens: The investigators use dexamethasone 10mg/d(d3-d7) as
      pre-processing therapy, dasatinib 100mg (d1-d84) plus prednisone 60mg/m2 (d1-24), reduce to
      d32, as inductive treatment after inductive treatment, if the patient get major molecular
      remission, patient will get to consolidation therapy, that is methotrexate (MTX) 3g/m2 d1, if
      not, this patient would be excluded from our trail. after consolidation therapy, if the
      patient have matched bone marrow donor, the investigators will suggest the patient receipting
      allogens-stem cell transplantation, otherwise, autogens stem cell transplantation can also be
      considered once the patient have no applicable bone marrow donor. on the other side, if the
      patient still not get MMR after this two cycle, maybe the patient can try Car-T, or other
      chemotherapy regimens.
    
  